Amongst sufferers with beforehand untreated, PD-L1-positive metastatic triple-negative breast most cancers (mTNBC), therapy with Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) has been...
Camrelizumab together with famitinib produced superior progression-free survival (PFS) outcomes versus platinum-based chemotherapy for the frontline therapy of sufferers with recurrent or...
Adjuvant therapy with Alecensa (alectinib) elicited a 4-year total survival (OS) fee of 98.4% for sufferers with resected ALK-positive early stage non–small...
Amongst sufferers with treatment-naïve superior melanoma, therapy with the investigational immune-modulatory therapeutic most cancers vaccine IO102-IO103 plus Keytruda (pembrolizumab) has been discovered...
Use of antibody-drug conjugates (ADCs) quickly on the rise amongst sufferers with breast most cancers, however age-based disparities stick with older ladies...
